Sialix is a biotechnology company developing products for the treatment and prevention of cancer. It uses a proprietary platform to develop therapeutic antibodies that target glycan alternations in cancer. Led by CEO Jeff Behrens, the company has offices in Cambridge, Massachusetts and a laboratory in San Diego, California. Sialix closed a $1.2M tranche of an angel-led financing and intends to use the funds to advance its products. The company previously signed a partnership agreement with Momenta Pharmaceuticals in 2012 and entered the Janssen Labs biotechnology incubator in early 2013. Backers in the financing included multiple angel groups and other undisclosed individuals. Sialix is a Cambridge, Mass.-based company developing products to treat and prevent cancer and chronic inflammatory conditions linked to ingestion of non-human sialic acids found in red meat and other dietary sources. The company is advancing two complementary programs: an oncology therapeutic targeting ovarian and other solid tumors, and a prophylactic nutritional supplement intended to reduce inflammation and the resulting risk of cancer and cardiovascular disease. Sialix is led by Jeff Behrens, president and CEO. The company raised $1M in financing from a group of angel investors. Backers included Boston Harbor Angels, Mass Medic Angels, Launchpad Angels, Maine Angels and other undisclosed individuals. As part of the financing, Brad Curley joined the board, Richard Anders will act as a board observer, and Dr. Peter Kiener will serve as a business and scientific advisor.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2014